Drug Trial Radar · NCT06942910
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
224
Actual
Start
May 7, 2025
Primary completion
Sep 26, 2026
Study completion Sep 26, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria
Conditions
- Chronic Kidney Disease With High Proteinuria
Interventions
Zibotentan/DapagliflozinDrug
Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
DapagliflozinDrug
Participants will receive monotherapy dapagliflozin as per the arms they are randomized to
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baselineTime frame: At Week 12
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Aramil, Russia
Research Site
Izhevsk, Russia
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Omsk, Russia
Research Site
Orenburg, Russia
Research Site
Perm, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saratov, Russia
Research Site
Saratov, Russia
Research Site
Ulyanovsk, Russia
Research Site
Yaroslavl, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.